2019 American Transplant Congress
Clazakizumab (CLZ, Anti-IL-6 Monoclonal Antibody) Treatment of Patients (Pts) with Chronic Antibody-Mediated Rejection (cABMR) Reduces Total Immunoglobulin (Ig) and Anti-HLA IgG Antibody Levels
Cedars-Sinai Medical Center, Los Angeles, CA
*Purpose: We have recently reported successful use of Tocilizumab (TCZ), an anti-IL-6 receptor (R) monoclonal antibody, for cABMR treatment in HLA-sensitized kidney transplant (KTx) Pts.…2019 American Transplant Congress
Desensitization Using Only IVIG: Is That an Option for Highly-Sensitized Patients Waiting for Kidneys from Cadaveric Donors?
Nefrologia, Hospital das Clínicas da Universidade de São Paulo, São Paulo, Brazil
*Purpose: The reduction of anti-HLA has been proven to be efficient and safe in transplants of highly-sensitized with living donors (LD). The results of adopting…2019 American Transplant Congress
The Effect of Intravenous Immunoglobulin on Human Complement-Dependent Cytotoxicity of Pig Cells: Benefit? Or Harm?
*Purpose: Xenoreactive antibodies and complement play an important role in pig xenograft rejection. Intravenous immunoglobulin (IVIG) is widely used in desensitization protocols and for the…2018 American Transplant Congress
The Complexity of HLA-DQ
Northwestern University, Chicago.
Historically, HLA-DQ antigens and antibodies (Ab) were difficult to classify due to the lack of serological typing reagents. However, with the advent of molecular typing…2018 American Transplant Congress
Comparison of C1Q Binding and Flow Cytometric Crossmatch Results Provides an Accurate Evaluation of Hypersensitive Kidney Transplant Patients
Measurement of C1q binding to Donor specific antibodies (DSA) gives transplantation chance to hypersensitive patients having non-binding high amount of anti-HLA antibodies. In our series…2018 American Transplant Congress
Temporal Variability of IgG Subclasses
Northwestern University, Chicago; Lurie Children's Hospital, Chicago.
The temporal model of IgG subclass switching supports sequential IgG conversion; however, the diversity of previously stimulated B cells is known to shape responses in…2018 American Transplant Congress
The Results of Plasmapheresis and Anti-CD20 Based Desensitization without Intravenous Immunoglobulin in Positive Crossmatch Kidney Transplants
Asan Medical Center, Seoul, Korea.
This study examined the mid-term clinical outcomes in positive crossmatch kidney transplants (XMKT) for patients who received desensitization with plasmapheresis (PP) and anti-CD20 based regimens…2018 American Transplant Congress
Early Adjunctive Treatment with Human Cytomegaly Virus (CMV) Immunoglobulin Increased CMV-Free Survival after Heart Transplantation
Purpose: There is still an ongoing discussion whether a prophylactic or a preemptive therapy against cytomegalovirus (CMV) is superior to reduce the incidence of CMV…2018 American Transplant Congress
Evanescent Antibodies: A Report on the Natural History of Anti-Blood Group A2 Antibodies and Their Rapid Resolution in Patients Awaiting A2 to B Transplantation
Medstar Georgetown Transplant Institute, Medstar Georgetown University Hospital, Washington, DC.
Introduction: Despite the benefits of A2 to B transplants, centers have been reluctant to adopt such a program due to unanswered questions including whether elevation…2018 American Transplant Congress
The Effect of Intravenous Immunoglobulin on In Vitro Human Antibody Binding to Genetically-Engineered Pig Cells – Relevance to Clinical Xenotransplantation –
Background: Xenoreactive antibodies play an important role in xenograft rejection. Intravenous immunoglobulin (IVIG), which has anti-complement activity and contains anti-idiotypic antibodies, is widely used for…
American Transplant Congress abstracts